Brief: Salarius Pharmaceuticals Says Now Determined To Close Ongoing Phase 1/2 Clinical Trial Evaluating Seclidemstat For Ewing Sarcoma

Decoy Therapeutics

19/07/2024 22:20

July 19 (Reuters) - Salarius Pharmaceuticals Inc
 SLRX.O :
    * SALARIUS PHARMACEUTICALS INC: NOW DETERMINED TO CLOSE
ONGOING
PHASE 1/2 CLINICAL TRIAL EVALUATING SECLIDEMSTAT FOR EWING
SARCOMA
    * SALARIUS PHARMACEUTICALS INC - TERMINATING THE ONGOING
CLINICAL
TRIAL IN AN EFFORT TO CONSERVE CASH
    * SALARIUS PHARMACEUTICALS INC: CONTINUES ITS EXPLORATION OF
POTENTIAL STRATEGIC ALTERNATIVES
    * SALARIUS PHARMACEUTICALS: TO CONTINUE SUPPORT FOR MDACC'S
SPONSORED CLINICAL TRIAL EVALUATING SECLIDEMSTAT (SP-2577) IN
COMBINATION WITH AZACITIDINE

Source text for Eikon:  ID:n0001615219-24-000058 
Further company coverage:  SLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))